Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12498
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChia, Puey Lingen
dc.contributor.authorMitchell, Paul L Ren
dc.contributor.authorDobrovic, Alexanderen
dc.contributor.authorJohn, Thomasen
dc.date.accessioned2015-05-16T02:12:14Z-
dc.date.available2015-05-16T02:12:14Z-
dc.date.issued2014-11-20en
dc.identifier.citationClinical Epidemiology 2014; 6(): 423-32en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12498en
dc.description.abstractImproved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.en
dc.language.isoenen
dc.subject.otheranaplastic lymphoma kinase (ALK)en
dc.subject.othergene rearrangementsen
dc.subject.otherkinase inhibitorsen
dc.subject.otherlung adenocarcinomaen
dc.subject.otherlung canceren
dc.titlePrevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical epidemiologyen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pathology, University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Health, Victoria, Australiaen
dc.identifier.doi10.2147/CLEP.S69718en
dc.description.pages423-32en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25429239en
dc.identifier.pubmedid25429239-
dc.type.austinJournal Articleen
local.name.researcherChia, Puey Ling
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.